Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rapport Therapeutics Inc (RAPP)

Rapport Therapeutics Inc (RAPP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,605,124
  • Shares Outstanding, K 47,800
  • Annual Sales, $ 0 K
  • Annual Income, $ -111,480 K
  • EBIT $ -125 M
  • EBITDA $ -125 M
  • 60-Month Beta 1.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.11

Options Overview Details

View History
  • Implied Volatility 84.05% (-4.40%)
  • Historical Volatility 58.00%
  • IV Percentile 23%
  • IV Rank 7.94%
  • IV High 295.21% on 08/29/25
  • IV Low 65.83% on 12/23/25
  • Expected Move (DTE 11) 4.59 (13.67%)
  • Put/Call Vol Ratio 1.67
  • Today's Volume 40
  • Volume Avg (30-Day) 29
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 452
  • Open Int (30-Day) 780
  • Expected Range 28.99 to 38.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.50
  • Number of Estimates 3
  • High Estimate $-0.16
  • Low Estimate $-0.70
  • Prior Year $-0.68
  • Growth Rate Est. (year over year) +26.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.01 +29.10%
on 03/19/26
34.00 -1.24%
on 04/02/26
+5.21 (+18.36%)
since 03/02/26
3-Month
25.21 +33.20%
on 02/05/26
34.00 -1.24%
on 04/02/26
+5.47 (+19.46%)
since 01/02/26
52-Week
7.73 +334.41%
on 05/30/25
42.27 -20.56%
on 09/08/25
+23.62 (+237.15%)
since 04/02/25

Most Recent Stories

More News
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting

BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery...

RAPP : 33.58 (+6.03%)
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

RAP-219’s lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026...

RAPP : 33.58 (+6.03%)
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China

Partnership leverages Tenacia’s expertise in central nervous system (CNS) drug development and commercialization to accelerate U.S. and global development of RAP-219 Tenacia obtains exclusive rights...

RAPP : 33.58 (+6.03%)
Rapport Therapeutics to Participate in Upcoming Investor Conferences

BOSTON and SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery...

RAPP : 33.58 (+6.03%)
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline

U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter...

RAPP : 33.58 (+6.03%)
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

BOSTON and SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery...

RAPP : 33.58 (+6.03%)
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures

Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients’...

RAPP : 33.58 (+6.03%)
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting

BOSTON and SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery...

RAPP : 33.58 (+6.03%)
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update

Positive topline results announced from Phase 2a clinical trial of RAP-219 in patients with focal onset seizures  Phase 2 trial of RAP-219 in bipolar mania enrolling patients and on track, with topline...

RAPP : 33.58 (+6.03%)
Rapport Therapeutics to Participate in Upcoming Investor Conferences

BOSTON and SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery...

RAPP : 33.58 (+6.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 38.07
2nd Resistance Point 36.03
1st Resistance Point 34.81
Last Price 33.58
1st Support Level 31.55
2nd Support Level 29.51
3rd Support Level 28.29

See More

52-Week High 42.27
Last Price 33.58
Fibonacci 61.8% 29.07
Fibonacci 50% 25.00
Fibonacci 38.2% 20.92
52-Week Low 7.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.